Clinical Trial Detail

NCT ID NCT04139902
Title PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Diwakar Davar
Indications

skin melanoma

melanoma

mucosal melanoma

acral lentiginous melanoma

Therapies

Dostarlimab + TSR-022

Dostarlimab

Age Groups: adult senior

No variant requirements are available.